Aoyagi S, Baker D H
Department of Animal Sciences, University of Illinois, Urbana 61801.
Poult Sci. 1993 Dec;72(12):2309-15. doi: 10.3382/ps.0722309.
Three chick experiments were conducted to evaluate a new Cu complex product, Cu-Met. Relative bioavailability of Cu was assessed with two bioassay systems, one employing bile Cu concentration as the criterion at Cu-deficient levels and another employing liver Cu concentration at Cu-excess levels. Relative bioavailability of Met was assessed separately. Common-intercept multiple linear regression (slope-ratio) of bile Cu concentration or liver Cu concentration regressed on supplemental Cu intake was used to assess Cu bioavailability relative to the standard, analytical-grade CuSO4.5H2O, which was set at 100%. In addition, Cu-Lys and CuCl (compounds previously evaluated by bile Cu concentration) were evaluated by the liver Cu accumulation method. Relative bioavailability of Cu in Cu-Met was estimated as 96% by the bile Cu assay and 88% by the liver Cu assay, which were not different (P > .05) from 100%. The liver Cu assay estimated that relative Cu bioavailabilities in Cu-Lys and CuCl of 114 and 145% (P < .05), respectively. These values were very close to those previously estimated by the bile Cu assay. Relative Met bioavailability of Cu-Met was 100% of the standard, i.e., feed-grade DL-Met.
进行了三项雏鸡试验以评估一种新型铜络合物产品——蛋氨酸铜(Cu-Met)。采用两种生物测定系统评估铜的相对生物利用率,一种在缺铜水平下以胆汁铜浓度为标准,另一种在铜过量水平下以肝脏铜浓度为标准。分别评估蛋氨酸的相对生物利用率。通过将胆汁铜浓度或肝脏铜浓度对补充铜摄入量进行共同截距多元线性回归(斜率比),来评估相对于标准分析级五水硫酸铜(设定为100%)的铜生物利用率。此外,通过肝脏铜蓄积法评估了赖氨酸铜和氯化铜(先前通过胆汁铜浓度评估的化合物)。通过胆汁铜测定法估计,Cu-Met中铜的相对生物利用率为96%,通过肝脏铜测定法为88%,与100%无差异(P>.05)。肝脏铜测定法估计,赖氨酸铜和氯化铜中铜的相对生物利用率分别为114%和145%(P<.05)。这些值与先前通过胆汁铜测定法估计的值非常接近。Cu-Met中蛋氨酸的相对生物利用率为标准品(即饲料级DL-蛋氨酸)的100%。